Relationship between serum prostate-specific antigen and calculated epithelial volume

Urology

Volumn 61, Issue 2, 2003, Pages 370-374

  Fukatsu, Akitoshi ^a   Ono, Yoshinari ^a   Ito, Masafumi ^a   Yoshino, Yasushi ^a   Hattori, Ryohei ^a   Gotoh, Momokazu ^a   Ohshima, Shinichi ^a  

^a NAGOYA UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

PROSTATE SPECIFIC ANTIGEN;

ADULT; AGED; ANALYTIC METHOD; ARTICLE; COMPUTER; CORRELATION ANALYSIS; EVALUATION; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; IMAGE ANALYSIS; MAJOR CLINICAL STUDY; MALE; MATHEMATICAL COMPUTING; ORGAN SIZE; PATHOGENESIS; PREOPERATIVE EVALUATION; PRIORITY JOURNAL; PROSTATE BIOPSY; PROSTATE EPITHELIUM; PROSTATE HYPERTROPHY; PROTEIN BLOOD LEVEL; TRANSURETHRAL RESECTION;

EID: 0037321413     PISSN: 00904295     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0090-4295(02)02159-3     Document Type: Article

References (25)

1. Hodge K.H., McNeal J.E., Terris M.K., et al. Random systematic versus directed ultrasound guided transrectal core biopsies of the prostate. J Urol. 142:1989;71-75.
2. Lui P.D., Terris M.K., McNeal J.E., et al. Indications for ultrasound guided transition zone biopsies in the detection of prostate cancer. J Urol. 153:1995;1000-1003.
3. Stamey T.A. Making the most out of six systematic sextant biopsies. Urology. 45:1995;2-12.
4. Norberg M., Egevad L., Holmberg L., et al. The sextant protocol for ultrasound-guided core biopsies of the prostate underestimates the presence of cancer. Urology. 50:1997;562-566.
5. Eskew L.A., Bare R.L., McCullough D.L. Systematic 5 region prostate biopsy is superior to sextant method for diagnosing carcinoma of the prostate. J Urol. 157:1997;199-203.
6. Catalona W.J., Beiser J.A., Smith D.S. Serum free prostate specific antigen and prostate specific antigen measurements for predicting cancer in men with prior negative prostate biopsies. J Urol. 158:1997;2162-2167.
7. Fowler J.E. Jr, Bigler S.A., Miles D., et al. Predictors of first repeat biopsy cancer detection with suspicious local stage prostate cancer. J Urol. 163:2000;813-818.
8. Borboroglu P.G., Comer S.W., Riffenburgh R.H., et al. Extensive repeat transrectal ultrasound guided prostate biopsy patients with previous benign sextant biopsies. J Urol. 163:2000;158-162.
9. Djavan B., Zlotta A., Remzi M., et al. Optimal predictors of prostate cancer on repeat prostate biopsy: a prospective study of 1,051 men. J Urol. 163:2000;1144-1149.
10. Papsidero L.D., Kuriyama M., Wang M.C., et al. Prostate antigen a marker for human epithelial cells . J Natl Cancer Inst. 66:1981;37-42.
11. Junk K., Stephan C., Lein M., et al. Analytical performance and clinical validity of two free prostate-specific antigen assays compared. Clin Chem. 42:1996;1026-1033.
12. Witherspoon L.R., Lapeyrolerie T. Sensitive prostate specific antigen measurements identify men with long disease-free intervals and differentiate aggressive from indolent cancer recurrences within 2 years after radical prostatectomy. J Urol. 157:1997;1322-1328.
13. Osterling J.E., Jacobsen S.J., Chute C.G., et al. Serum prostate-specific antigen in a community-based population of healthy men establishment of age-specific reference ranges . JAMA. 270:1993;860-864.
14. Stamey T.A., Yang N., Hay A.R., et al. Prostate-specific antigen as a serum marker for adenocarcinoma of the prostate. N Engl J Med. 317:1987;909-916.
15. Babaian R.J., Kojima M., Ramirez E.I., et al. Comparative analysis of prostate specific antigen and its indexes in the detection of prostate cancer. J Urol. 156:1996;432-437.
16. Roehrborn C.G., McConnell J., Bonilla J., et al. Serum prostate specific antigen is a strong predictor of future prostate growth in men with benign prostatic hyperplasia. J Urol. 163:2000;13-20.
17. MacNeal J.E. Anatomy of the prostate and morphogenesis of BPH. Prog Clin Biol Res. 145:1984;27-53.
18. Hammerer P.G., McNeal J.E., Stamey T.A. Correlation between serum prostate specific antigen levels and the volume of the individual glandular zones of the human prostate. J Urol. 153:1995;111-114.
19. Cadeddu J.A., Partin A.W., Pearson J.D., et al. Relationship between changes in prostate-specific antigen and the percent of prostatic epithelium in men with benign prostatic hyperplasia. Urology. 45:1995;795-800.
20. Lepor H., Wang B., Shapiro E. Relationship between prostatic epithelial volume and serum prostate-specific antigen levels. Urology. 44:1994;199-205.
21. Lepor H., Shapiro E., Wang B., et al. Comparison of benign prostatic hyperplasia in Chinese and Caucasian-American men. Urology. 47:1996;38-42.
22. Weber J.P., Oesterling J.E., Peters C.A., et al. The influence of reversible androgen deprivation on serum prostate-specific antigen levels in men with benign prostatic hyperplasia. J Urol. 141:1989;987-992.
23. Shapiro E., Hartanto V., Lepor H. Anti-desmin vs. anti-actin for quantifying the area density of prostate smooth muscle. Prostate. 20:1992;259-267.
24. Maeda H., Arai Y., Aoki Y., et al. Complexed prostate-specific antigen and its indexes in the detection of prostate cancer. Urology. 54:1999;225-228.
25. Egawa S., Suyama K., Matsumoto K., et al. Prospective evaluation of cancer detection by prostate specific antigen related parameters comparison in serum and plasma samples . J Urol. 167:2002;97-102.